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receptor That co-segregates With 
autosomal-Dominant hypocalcemia
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1 Research Centre of Ageing and Osteoporosis, Department of Endocrinology, Rigshospitalet, Copenhagen,  
Denmark, 2 Department of Clinical Biochemistry, Rigshospitalet, Copenhagen, Denmark, 3 Institute of Clinical 
Research, University of Southern, Odense, Denmark, 4 Faculty of Health Sciences, Copenhagen University, 
Copenhagen, Denmark
The human calcium-sensing receptor (CASR) is the key controller of extracellular Ca 2+o  
homeostasis, and different mutations in the CASR gene have been linked to different 
calcium diseases, such as familial hypocalciuric hypercalcemia, severe hyperparathy-
roidism, autosomal-dominant hypocalcemia (ADH), and Bartter’s syndrome type V. 
In this study, two generations of a family with biochemically and clinically confirmed 
ADH who suffered severe muscle pain, arthralgia, tetany, abdominal pain, and fatigue 
were evaluated for mutations in the CASR gene. The study comprises genotyping of 
all family members, functional characterization of a potential mutant receptor by in vitro 
analysis related to the wild-type receptor to reveal an association between the geno-
type and phenotype in the affected family members. The in vitro analysis of functional 
characteristics includes measurements of inositol trisphosphate accumulation, Ca2+ 
mobilization in response to [Ca2+]o-stimulation and receptor expression. The results 
reveal a significant leftward shift of inositol trisphosphate accumulation as a result of 
the “gain-of-function” mutant receptor and surprisingly a normalization of the response 
in (Ca2+)i release in the downstream pathway and additionally the maximal response 
of (Ca2+)i release was significantly decreased compared to the wild type. However, no 
gross differences were seen in D126V and the D126V/WT CASR dimeric >250 kDa 
band expression compared to the WT receptor, however, the D126V and D126V/WT 
CASR immature ~140 kDa species appear to have reduced expression compared to 
the WT receptor. In conclusion, in this study, a family with a clinical diagnosis of ADH 
in two generations was evaluated to identify a mutation in the CASR gene and reveal 
an association between genotype and phenotype in the affected family members. The 
clinical condition was caused by a novel, activating, missense mutation (D126V) in the 
CASR gene and the in vitro functional characteristics of the mutation co-segregated 
with their individual phenotype.
Keywords: calcium-sensing receptor, “gain-of-function” mutation, gPcr, signaling, aDh
Table 1 | The biochemical baseline characteristics of the ADH family members investigated.
Patient age 
(years)
bMi bMD(l2–l4) 
(g/cm2)
s-ca(total) 
(mmol/l)
s-ca2+ 
(mmol/l)
s-PTh(1–84) 
(pmol/l)
s-PO4− 
(mmol/l)
s-Mg2+ 
(mmol/l)
s-1,25(Oh)2D 
(pmol/l)
s-25(Oh)D 
(nmol/l)
U-ca 
(mmol/l)
Ref. range
DS/EN ISO 
15189:2013
2.20–2.60 1.15–1.35 1.1–6.9 0.80–1.50 0.67–0.93 51–177 50–160 2.00–7.00
Ι-1♂ 47 NA NA NA 1.21 6.9 NA NA NA 68 NA
Ι-2♀ 42 24.1 1.107 1.90 1.02 <0.6 1.0 0.65 130 26 4.7
ΙΙ-1♂ 19 22.4 0.580 2.48 1.26 1.9 NA NA NA 24 5.9
ΙΙ-2♂ 17 19.8 0.914 2.08 1.06 0.9 0.99 0.78 99 45 6.5
ΙΙ-3♀ 16 17.9 1.084 1.89 1.02 1.3 1.54 0.73 113 56 5.2
Data in bold are out of reference range.
NA, not analyzed; ADH, autosomal-dominant hypocalcemia; PTH, parathyroid hormone; BMD, bone mineral density.
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inTrODUcTiOn
In humans, extracellular calcium concentrations ((Ca2+)o) play a 
key role in most vital physiological processes, and thus a tight 
control of (Ca2+)o is critically important. The G protein-coupled 
calcium-sensing receptor (CASR) plays a major role in systemic 
calcium homeostasis. The most important physiological function 
of CASR is to maintain and regulate (Ca2+)o. In humans, CASR 
is highly expressed on the cell membrane of the chief cells of 
the parathyroid glands, where it "senses" the change in (Ca2+)o 
and subsequently generates and alters the release of parathyroid 
hormone (PTH) (1, 2). Moreover, CASR is functionally expressed 
in the bone, kidney, and gut, the three major organs involved in 
calcium homeostasis. (Ca2+)o has key roles in bone biology, in the 
regulation of different hormones, and in various cellular func-
tions. CASR is the first known receptor that permits an ion (Ca2+) 
to have a “hormone like” role as a first messenger in addition to 
its well-known role as an intracellular second messenger (3–6). 
In the kidney, CASR plays a pivotal role in renal calcium reabsorp-
tion and excretion (7), whereas it regulates calcium absorption in 
the intestine (8, 9). In bone, CASR controls the mineralization of 
the matrix and regulates bone turnover (10). The blood ionized 
calcium concentration results from the balance between intestinal 
calcium absorption, renal calcium reabsorption, and/or calcium 
release from bones. In humans, CASR responds to even very 
small fluctuations in the (Ca2+)o, and PTH acts within seconds 
or minutes to reestablish the (Ca2+)o in humans, showing a very 
steep inverse sigmoidal relationship between (Ca2+)o and PTH 
(1, 2, 11). The calcium set-point has been used for the clinical 
evaluation of calcium-related diseases (12–14). If the regulation 
of (Ca2+)o fails, several vital organs will be affected. Most impor-
tantly, hypocalcemia will induce increased excitability of the 
nervous system with a risk of tetany, which occurs when (Ca2+)o 
is reduced by 0.40 mmol/L below baseline (15).
The receptor is activated when endogenous ligands bind to one 
of the three binding sites in the large N-terminal “Venus FlyTrap” 
domain and/or to the one in the cys-rich domain, respectively 
(16). Consequently, changing the configuration of the receptor and 
subsequently the downstream signaling and interaction with the 
associated G-protein. The primary endogenous ligand of CASR is 
(Ca2+)o, although CASR also responds to other inorganic di- and 
trivalent cations, as well as naturally occurring l-amino acids (17). 
The principal signaling pathway of CASR is the Gαq/11-activated 
phospholipase Cβ pathway (PI-PLC). (Ca2+)o binding to dimeric 
CASR activates the receptor, mediates the accumulation of inositol 
trisphosphate (IP), and subsequently increases the intracellular 
Ca2+ concentrations ((Ca2+)i) via mobilization from intracellular 
stores (18, 19). In human parathyroid cells, the increase in (Ca2+)i, 
together with vitamin D response element, inhibits the transcrip-
tion of the gene encoding PTH (20, 21), generating an increase in 
renal Ca2+ excretion and subsequent a decrease in intestinal Ca2+ 
absorption, which results in a decrease in (Ca2+)o (22, 23).
A number of mutations in the CASR gene have been shown 
to affect calcium homeostasis by changing the calcium set point, 
PTH secretion, bone resorption, and renal calcium excretion. 
Clinically, mutations in CASR can either cause hypercalcemia if 
the receptor is inactivated (loss-of-function), resulting in familial 
hypocalciuric hypercalcemia, or hypocalcemia if the receptor is 
activated (gain-of-function) to produce a hypersensitive receptor, 
causing autosomal-dominant hypocalcemia (ADH) (13). Recent 
studies have shown that the pleiotropic CASR gene induces 
agonist- and ligand-biased signaling via pathways coupled to 
the PI-PLC, p38 MAPK, and JNK pathways (24–27), indicating 
that the signaling bias is an important property of the recep-
tor function that might explain the key differences in receptor 
function between tissues and the patterns of diseases arising 
from specific disease-related mutations. We report here a novel 
“gain-of-function” mutation of the CASR that co-segregated with 
the individual phenotype in two generations diagnosed ADH. 
The results indicate that the naturally occurring mutation in the 
receptor may have engendered a change in receptor conformation 
that biases the signaling.
sUbJecTs anD MeThODs
Patients
In this study, two generations with biochemically and clinical 
confirmed ADH who suffered from severe muscle pain, arthral-
gia, tetany, abdominal pain, and fatigue were evaluated for 
mutations in the CASR gene. The proband, individual I-2, was 
a 42-year-old woman who suffered from chronic hypocalcemia, 
i.e., a serum ionized calcium concentration of <1.15  mmol/L, 
with no increase in serum PTH levels, normal kidney func-
tion, low serum 25-hydroxyvitamin D levels, and normal 1,25- 
dihydroxyvitamin D levels (Table 1). Her baseline values were 
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further controlled to exclude Bartter’s syndrome and she had a 
S-sodium of 143 mmol/L, S-potassium 3.9 mmol/L, S-creatinine 
of 89 mmol/L, S-magnesium of 0.65 mmol/L, and the U-Ca/Crea 
was 0.12 (reference < 0.14).
One child (II-3) showed clinical symptoms that were similar 
to the proband. Family members II-2 and II-1 reported some 
clinically insignificant symptoms of skeletal and muscle pain. 
Dual-energy X-ray absorptiometry-scanning of the spine and 
hip showed that family member II-2 (17  years, male, height 
180  cm, weight 64.0  kg) was osteopenic, with a bone mineral 
density (BMD) of 0.914 g/cm2 at the lumbar spine (L2–L4). Family 
member II-1 (19 years, male, height 187 cm, weight 78.2 kg) had a 
low BMD of 0.580 g/cm2 at the lumbar spine (L2–L4). The proband 
(height 169 cm, weight 68.9 kg) and II-3 (II-3, 16 years, female, 
height 164 cm, weight 48.1 kg) both had normal lumbar spine 
BMD values of 1.107 and 1.084 g/cm2, respectively. The proband 
and the II-3 showed micro calcifications in various tissues in addi-
tion to nephrocalcinosis. In addition, the proband had Quincke’s 
edema, symptoms of urticaria, decreased muscle strength, 
and infrequent muscle cramps in the extremities, whereas II-3 
showed additional frequent depressive periods. The baseline bio-
chemical characteristics are presented in Table 1. An evaluation 
of urinary calcium excretion showed that the levels were between 
5 and 9 mM/day in all affected family members. Peripheral blood 
was collected by venipuncture from the proband, her husband, 
and their three children to genotype the CASR mutations. The 
participants gave written consent for use of biological material for 
scientific purposes. The study was approved by the Unit of Health 
Care, Regional Scientific Ethical Committee, The Capital Region 
of Denmark (J.no.17011317).
Methods
Sequence Analysis
DNA was purified from peripheral blood and the sequences of 
the UTR exon 1A/B and the protein-coding exons 2–7 of the 
CASR gene, including the related boundaries, were analyzed after 
designing primers for all 9 exons used for PCR amplification, in 
addition to direct sequence analysis of the PCR amplicons (see the 
nucleotide sequences for the primers in Table S1 in Supplementary 
Material). The DNA sequences were amplified using standard PCR 
techniques as follows: 1 cycle of denaturation at 94°C for 10 min, 
then 30 cycles of denaturation at 94°C for 30 s, hybridization of the 
designed primers at 60°C for 30 s, except for the primers for exon 
4 which were hybridized at 62°C for 30 s, and subsequent elonga-
tion at 72°C in 30  s, followed by a final elongation at 72°C for 
10 min. Ampli Taq-gold DNA polymerase (Applied Biosystems, 
Foster City, CA, USA) was used to amplify all exons. The PCR 
amplicons were verified by gel electrophoresis. Subsequently, the 
nucleotide sequence of both strands was determined by direct 
sequencing using the ABI Prism® BigDye™ Terminator, which 
was analyzed on an Applied Biosystems 3100 Genetic Analyzer 
(ABI3100), according to the manufacturers’ instructions. The 
nucleotide sequence identified by the ABI3100 was analyzed with 
the SeqScape Software ver. 2.0 (Applied Biosystems) to confirm 
any variations, single-nucleotide polymorphisms or mutations 
using the reference sequence of the CASR gene (NG_009058).
Construction of the Wild-Type and Mutant  
CASR Vector
The wild-type calcium-sensing receptor vector (WT-CASR) is a 
construct of the Human Pearce cassette WT-CASR cDNA cloned 
into the pcDNA3.1(+)vector (Invitrogen™, Thermo Fisher 
Scientific Inc., MA, USA) using the Kpn I and Xba I restriction 
sites in the multiple cloning site of the pcDNA3.1(+)vector and 
was termed rHuPCAR4.0 (28). The rHuPCAR4.0 vector was 
supplied by A.D. Conigrave, School of Molecular and Microbial 
Biosciences, University of Sydney, NSW, Australia, and origi-
nated from M. Bai and E. M. Brown, Division of Endocrinology, 
Diabetes, and Hypertension, Department of Medicine, Brigham 
and Women’s Hospital, Boston, MA, USA. Site-directed 
mutagenesis was performed on the human WT-CASR cDNA 
pc3.1DNA(+)vector to produce the specific missense mutation 
corresponding to substitution of an adenosine nucleotide (A) 
for thymidine (T) in codon 126 (GAT) of the CASR gene, which 
causes a change from the amino acid aspartic acid to valine in 
the receptor protein. The site-directed mutagenesis and subse-
quent control sequencing were performed by Eurofins Genomic, 
Ebersberg, Germany.
Cell Culture
Flp-In human embryonic kidney-293 (HEK293) cells were 
cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) 
with 4.5  g/L glucose and l-glutamine (Lonza #614712F, Basel, 
Switzerland) supplemented with 10% fetal calf serum (FCS), 0.5 U/
mL penicillin, 0.5 mg/mL streptomycin, and zeocin 0.1 mg/mL 
(Invitrogen™). The cells were maintained in a T-175 cell flask 
and incubated at 37°C in a humidified 5% CO2 atmosphere. The 
Flp-In HEK293 cells were a gift from Hans Braüner-Osborne, 
Department of Drug Design and Pharmacology, Faculty of Health 
and Medicine Science, University of Copenhagen, Denmark.
Transfection of Cells
The plasmids encoding the mutant and WT receptors were 
transiently transfected into Flp-In HEK293 cells to study the 
functional characteristics of the mutant CASR protein in  vitro. 
One day before the transient transfection of the cells for the func-
tional assays, 2 × 104 cells per well were seeded into a clear 96-well 
plate for the IP assay and into a black, clear bottom plate for the 
(Ca2+)i mobilization assay. For the Western blot experiments, 
1 × 106 cells per well were seeded in 6-well plates. The plates were 
coated with poly-d-lysine (50 µg/mL) to allow for sufficient cell 
adhesion. On the following day, the cells were transfected with 
either 0.25  μg/well of the WT-CASR-pcDNA3.1(+), mutant-
CASR-pcDNA3.1(+), WT- and mutant-CASR-pcDNA3.1(+), or 
mock-vector using Lipofectamine (Invitrogen™) in a 1:1 ratio 
for the functional assays. However, for Western blotting, a 1:2.5 
ratio was transfected according to the manufacturer’s protocol. 
The cells were maintained 16–24 h in DMEM with 4.5 g/L glucose 
and l-glutamine (Lonza # 614712 F) and 10% FCS. The cells were 
incubated at 37°C in a humidified 5% CO2 atmosphere.
IP Accumulation Assay
In vitro functional characterization of the individual receptor 
proteins was performed within 48 h of the transfection. The cells 
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were analyzed for accumulation of soluble inositol phosphate 
(IP) in the presence of lithium, using a phosphatidylinositol 
hydrolysis assay as previously described (29). In brief, the day 
after transfection, the cells were washed twice with assay buffer 
(HBSS with calcium and magnesium) (Life Technologies # 14025, 
Thermo Fisher Scientific Inc., MA, USA), supplemented with 
20 mM HEPES (Life Technologies # 15630-056, Thermo Fisher 
Scientific Inc., MA, USA, at pH 7.4), and incubated 16–24 h with 
100 µl of inositol-free DMEM (MP Biomedical, Santa Ana, CA, 
USA cat # 1642954) supplemented with 10% FCS and 1  μCi/
well myo-[2-3H] Inositol (code TRK 911, GE Healthcare, Little 
Chalfont, UK). After incubation, the medium was removed; the 
cells were washed twice with assay buffer, and then incubated 
with 100  µl of assay buffer supplemented with 10  mM LiCl 
preventing dephosphorylation of the accumulated IP by inositol 
phosphatase for 20 min at 37°C. The buffer was removed, and the 
cells were incubated with 100 µL of HBSS buffer without calcium 
and magnesium supplemented with 10  mM LiCl and various 
concentrations of CaCl2 for 60 min. The reactions were stopped 
by exchanging the buffer with 50 µL of ice-cold 20 mM formic 
acid and incubated for 1 h on ice to release the IP generated by 
the cells. Thirty microliters of the lysis solution were transferred 
to a solid white flat bottom 96-well plate (NUNC, Thermo Fisher 
Scientific Inc., MA, USA) and 1  mg/mL SPA-YSi scintillation 
beads (PerkinElmer, Boston, MA, USA) was added to each well. 
The plate was sealed, shaken for 1 h, and centrifuged at 1,500 rpm 
for 5 min. The labeled IP was measured by detecting the emitted 
light using a MicroBeta2 Plate Counter (PerkinElmer).
(Ca2+)i Mobilization Assay
In vitro functional characterization of the individual receptor 
proteins was performed within 48 h of the transfection. The cells 
were analyzed for the release of (Ca2+)i from the endoplasmic 
reticulum, as previously described (30). In brief, the medium was 
removed from the cells, 50 µl of assay buffer (HBSS w/o calcium 
and magnesium) (Life Technologies # 14175) supplemented with 
1 mM CaCl2, 1 mM MgCl2, 20 mM HEPES, 2.5 mM probenecid, 
and 4 µM fluo-4AM (acetoxymethyl ester) (Invitrogen™), pH 7.4, 
were added, and the cells incubated for 1 h at 37°C in a humidi-
fied 5% CO2 atmosphere. The cells were washed with wash buffer 
(assay buffer without fluo-4AM) and were placed in the incubator 
for 30 min after the addition of 100 µl of fresh wash buffer. (Ca2+)i 
release was quantified by measuring the fluorescence at 485 nm 
excitation and 525  nm emission on a NOVOstar (Molecular 
Devices; Sunnyvale, Ca, USA) for 60 s after the addition of vari-
ous concentrations of CaCl2. Changes in the relative fluorescence 
units [ΔRFU = (F − F0)/F0] of Fluo-4 AM-loaded Flp-In HEK293 
cells were calculated to adjust for the differences in cell number 
and loading efficiency (F expresses the maximal response of 
fluorescence, F0 expresses the basal response of fluorescence.).
Immunoblotting
In vitro functional characterization of the individual receptor 
proteins was performed within 48  h of the transfection. The 
cells were washed once with ice-cold phosphate-buffered saline. 
Afterward, the cells were lysed in ice-cold lysis-buffer (10 mM 
Tris–HCl, pH 7.4, 10 mM NaCl2, 3 mMgCl2, and 1 mM EDTA) 
containing 3% NP-40 detergent and 12.5% protease inhibitors 
(Complete tablets, ref # 04693116001, Hoffmann-La-Roche, 
Basel, Switzerland). The lysed cells were scraped and transferred 
to an Eppendorf tube for centrifugation at 500 × g for 5 min at 
4°C. The supernatant corresponding to the cytosol and plasma 
membrane was removed and not assayed. The remaining pellet 
containing nuclei was washed with lysis buffer without NP-40, 
centrifuged at 500 × g for 5 min at 4°C, dissolved in 10 mM Tris–
HCl, pH 7.4, with 2% SDS, sonicated, and stored at −20°C until 
further analysis. The total protein concentrations were measured 
using the Bio-Rad protein assay, according to the manufacturer’s 
instructions. Each cell fraction was diluted in Loading buffer 
(4xLDS, Ken-en-Tec, Taastrup, DK #B31010) and 0.05 M DTT 
(Sigma-Aldrich, St. Louis, MO, USA; #D-9770-10), boiled for 
2  min; protein equivalents of 20  µg per lane were separated 
on a 10% SDS-PAGE gel. After separation, the proteins were 
electro-transferred to a nitrocellulose membrane for Western 
blotting. The presence of proteins expressed from the WT-CASR-
pcDNA3.1(+), mutant-CASR-pcDNA3.1(+), WT-CASR- and 
mutant-CASR-pcDNA3.1(+), and the mock-vector was detected 
by incubating the membranes 16–24  h at 4°C with 1  µg/mL 
anti-CASR rabbit polyclonal antibody raised against amino acids 
111–210 within the N-terminal ECD of human CASR (Santa 
Cruz Biotechnology Inc., Santa Cruz, CA, USA; Cat.# sc-33821). 
Subsequently, the membrane was incubated with a horseradish 
peroxidase-conjugated goat anti-rabbit secondary antibody at 
a dilution of 1:5,000 for 1 h at room temperature. The receptor 
proteins were visualized using chemiluminescence with the ECL 
Advance Western Blotting Detection reagent (GE Healthcare). 
The chemiluminescence of the CASR protein was detected using 
the ImageQuant LAS-4000, Fujifilm (GE Healthcare).
Data analysis and statistics
Data from the [Ca2+]o dose–response experiments were fitted to 
the four parameter dose-response curve using GraphPad Prism 
ver.6.0 (GraphPad, San Diego, CA, USA) the following variable 
slope equation: R = Rmin + (Rmax − Rmin)/(1 + 10((LogEC50-X) * Hill 
slope)) where R is the response, X is the logarithm of the [Ca2+]o 
concentration, Rmax is the maximal response, Rmin is the minimal 
response, EC50 is the agonist concentration that produces a 
half maximal response, and Hill slope describes the steepness 
of the curve. Based on the individual fitted curves the mean and 
SD values were calculated. To determine whether any statisti-
cally significant differences in Emax values were present, data 
were transformed to percent of the WT-CASR Emax (WT being 
100%). Normality of data was tested by Shapiro–Wilks normal-
ity test. For normally distributed data (EC50 and Hill slope) 
one-way analysis of variance was used. For non-normally dis-
tributed data (Emax) Kruskal–Wallis test was applied. Equality 
of variance between groups was tested by Brown–Forsythe 
and Bartlett’s test. Appropriate post  hoc tests (the parametric 
Tukey’s multiple comparisons test and the non-parametric 
Dunn’s multiple comparisons test) were applied. All statistical 
analyses were done using GraphPad Prism v. 6.0. The statisti-
cal significance of induced [Ca2+]o effects on the mutant- and 
WT-CASR regarding Hill slope, efficacy and potency, was con-
sidered at P < 0.05.
FigUre 1 | The DNA sequence of codon 123–129 of the calcium-sensing 
receptor (CASR) gene in the affected family members. The DNA sequence 
analysis of exon 3 reveal a nucleotide substitution of adenine (A) to thymidine 
(T) in codon 126 of the CASR gene; subsequently changing the amino acid 
aspartic acid (D) (GAT) to valine (V) (GTT). The heterozygous A/T mutant 
sequence of codon 126 was identified in I-2, II-2, and II-3.
FigUre 2 | Genotype and pedigree of the family investigated. The nucleotide substitution was identified in I-2 (proband) and in II-2 and II-3 both affected progeny  
of the proband. The proband and the affected progeny all have S-calcium below reference range, I-2 had severe muscle pain, tetany, and depression; II-2 had 
gentle muscle pain; and II-3 had diffuse muscle pain and depression. Wild-type homozygous A/A of codon 126 is the open boxes; black boxes are the 
heterozygous mutant A/T codon.
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resUlTs
inheritance of a novel activating Mutation
A novel heterozygous genotype, D126V, of the CASR gene 
was identified, and the pedigree showed autosomal-dominant 
inheritance. The DNA sequence analysis revealed a novel mis-
sense mutation in exon 3 that was initiated by an adenine (A) 
to thymidine (T) substitution in codon 126(GAT), changing an 
aspartic acid (D) to valine (V) D126V(GTT) (Figure 1).
The nucleotide substitution was identified in I-2 (proband), 
II-2, and II-3, all of whom were diagnosed with ADH, with 
S-calcium(total) levels of 1.89–2.08 mmol/L (ref. 2.20–2.60 mmol/L) 
and S-iPTH levels ranging 0.6–1.09 pmol/L (ref. 1.1–6.9 pmol/L). 
The proband and two of her children were heterozygous carri-
ers of the D126V mutation. The pedigree showed that D126V 
mutant allele was inherited in an autosomal-dominant manner 
(Figure 2), which is in accordance with the baseline biochemical 
parameters (Table 1).
The Mutant CASR-Mediated iP 
accumulation, showing increased 
Potency and a Decreased hill slope 
compared to the WT receptor
First, we determined the functional effects of the homozygous 
D126V-CASR and heterozygous D126V/WT-CASR receptors 
compared to the homozygous WT-CASR receptor at the first point 
of PI-PLC pathway activity in vitro by measuring IP accumulation 
in response to stimulation with 0.5–15  mM [Ca2+]o for 60  min. 
We observed a more left-shifted response for cells expressing 
the homozygous D126V-CASR compared to the cells expressing 
heterozygous D126V/WT receptor and the cells expressing the 
WT-CASR (Figure 3).
Moreover, the potency increase was significant for the cells 
expressing D126V-CASR compared to the cells expressing the 
WT-CASR protein, the EC50 values were 3.24 ± 0.3 mM (P < 0.05) 
and 5.05 ± 0.7 mM, respectively, in accordance with a “gain-of- 
Table 2 | Pharmacological parameters.
iP acc. (ca2+)i-mobilization
ec50 mM hill slope Emax% ec50 mM hill slope Emax%
WT-CASR 5.05 ± 0.7 3.16 ± 0.4 100 1.82 ± 0.2 1.96 ± 0.1 100
D126V-CASR 3.24 ± 0.3a 2.22 ± 0.3 111 ± 12 1.46 ± 0.2 2.15 ± 0.2 50 ± 4b
WT/D126V-CASR 3.57 ± 0.3 2.42 ± 0.1 86 ± 9 1.51 ± 0.2 2.15 ± 0.2 72 ± 4
The potency (EC50), the Hill slope and the efficacy (Emax) for [Ca2+]o− stimulation of Flp-IN HEK293 cells transiently transfected with the WT-CASR, the D126V-CASR, the WT/D126V-
CASR. Data shown as mean ± SEM from five/six experiments performed in duplicate.
aSignificant from WT-CASR, P < 0.05.
bSignificant from WT-CASR, P < 0.01.
WT-CASR, wild-type calcium-sensing receptor; HEK293, human embryonic kidney-293.
FigUre 3 | The effect of [Ca2+]o-induced PI-PLC activation in cells transfected with WT- or mutated calcium-sensing receptor (CASR) gene. Dose-response of IP 
accumulation (CPM) of [Ca2+]o-induced PI-PLC activation. Flp-IN human embryonic kidney-293 (HEK293) cells were transiently transfected with the wild-type 
calcium-sensing receptor (WT-CASR) (●), D126V-CASR (▿), WT/D126V-CASR (▵), or mock vector (■) were exposed to various [Ca2+]o concentrations and IP 
accumulation was analyzed. Data are mean ± SD of a single representative experiment performed in duplicates. Four additional experiments gave similar results.
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function” mutation. According to the D126V/WT-CASR there 
were no significant difference of the EC50 values compared to the 
WT-CASR, EC50 values were 3.57 ± 0.3 mM and 5.05 ± 0.7 mM, 
respectively.
The Hill slope of the homozygous D126V- and the heterozygous 
D126V/WT-CASR receptor was D126V =  2.22 ±  0.3, D126V/
WT = 2.42 ± 0.1, than cells expressing the WT receptor revealed 
a Hill slope at 3.16 ± 0.4. The efficacy for both the D126V-CASR 
and the D126V/WT receptors were similar to the homozygous 
WT receptor, Emax =  111 ±  12% and 86 ±  9% (Table  2). The 
cells transfected with the mock vector did not show any dose-
dependent response to [Ca2+]o stimulation. The results for the 
homozygous genotype D126V-CASR are in accordance with a 
“gain-of-function" mutation of the CASR gene.
The Mutant CASR-Mediated (ca2+)i 
Mobilization, showing similar hill slope 
and Potency and Decreased efficacy 
compared to the WT receptor
We next investigated the effects of the mutation on downstream 
Gq/11 signaling by measuring (Ca2+)i mobilization in response 
to [Ca2+]o stimulation. In the functional assay, FLIPR, Fluo-4 
AM-treated cells were stimulated with 0.5–12  mM [Ca2+]o for 
60  s, and (Ca2+)i mobilization was measured continuously. 
Interestingly, a remarkable reduction in the efficacy of the cells 
expressing the homozygous D126V-CASR was observed, as 
there was a highly significant decrease in the efficacy (Emax) to 
50 ± 10% (P < 0.01) compared to WT. For the cells expressing 
FigUre 4 | The effect of [Ca2+]o-induced (Ca2+)i-mobilization in cells transfected 
with WT- or mutated calcium-sensing receptor (CASR) gene. Dose-response of 
relative fluorescence units (RFU) of [Ca2+]o-induced (Ca2+)i-mobilization. Flp-IN 
human embryonic kidney-293 cells were transiently transfected with the wild-type 
calcium-sensing receptor (WT-CASR) (●), D126V-CASR (▿), WT/D126V-CASR (▵), 
or mock vector (■) were incubated with 4 µM fluo-4AM, washed, and (Ca2+)i 
release was quantified after addition of various concentrations of [Ca2+]o. Data are 
mean ± SD of a single representative experiment performed in duplicates. Five 
additional experiments gave similar results.
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the heterozygous mutant CASR (WT/D126V) the efficacy was 
72 ± 9% (Figure 4). By contrast, no differences in potency were 
observed between cells expressing the homozygous or heterozy-
gous D126V mutations compared to the WT-CASR, with EC50 
values of 1.46 ± 0.2 mM for D126V, 1.51 ± 0.2 mM for D126V/WT, 
and 1.82 ± 0.2 mM for WT (Table 2) (Figure 4).
Moreover, the Hill slope of the mutant receptors was not sig-
nificantly different from the Hill slope in cells expressing the WT 
receptor, with Hill slopes for the homozygous D126V receptor of 
2.15 ± 0.2, the heterozygous D126V/WT receptors of 2.15 ± 0.2, 
and the WT receptor of 1.96 ± 0.1 (Table 2).
The Total receptor expression of the 
Mutant CASR Was similar to the WT 
receptor in the immunoblot analysis
Finally, we investigated the total receptor expression of the WT 
and mutant receptors. Western blot analysis of the nuclear cell 
fraction confirmed expression of the immature 140  kDa, the 
mature 160  kDa and the functional dimeric receptor protein 
>240  kDa (Figure  5A). The mature 160  kDa could not be 
assessed due to the presence of a band at the same size in the 
mock-vector (GFP) sample used as a transfection control. 
No gross differences were seen in D126V and the D126V/WT 
CASR dimeric >250 kDa band expression compared to the WT 
receptor, however, the D126V and D126V/WT CASR immature 
~140 kDa species appear to have reduced expression compared 
to the WT receptor. This may indicate an abnormality in matura-
tion of the receptor which might contribute to explaining the 
functional effects noted.
DiscUssiOn
In this study, a novel, activating, missense mutation of the CASR 
gene, which is responsible for ADH, was identified and func-
tionally characterized. The heterozygous GAT > GTT mutation 
FigUre 5 | Evaluation of the WT- and the mutant calcium-sensing receptor (CASR) expression in transiently transfected Flp-In human embryonic kidney-293 
(HEK293) cells. (a) Western blot analysis of the nuclear cell fraction, expression the band of the immature 140 kDa, the mature 160 kDa, and the functional dimeric 
receptor protein >240 kDa. Lane 1: WT/D126V-CASR, lane 2: D126V-CASR, lane 3: wild-type calcium-sensing receptor (WT-CASR), lane 4: mock-vector fused with 
GFP for transfections control, lane 5: ladder. WB on β-actin was used as loading control. Four additional experiments gave similar results. Panel (b) shows the light 
microscopy and the fluorescent microscopy of Fl-In HEK293 cells transfected with the GFP-vector.
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the effects on IP accumulation, in accordance with the study 
by Goolam et al. (27). [Ca2+]o stimulation had little effect on 
(Ca2+)i mobilization, as normalization of potency and Hill 
slope were observed for both the heterozygous and homozy-
gous receptors. Conversely, a remarkably significant impaired 
efficacy of the cells expressing the homozygous D126V-CASR 
was shown for this later point of the Gq/11 signaling pathway 
(Table 2; Figure 4), which is different from the results reported 
by Leach (26). We hypothesize that D126V enhances pathway 
desensitization by depleting the (Ca2+)i stores and changing the 
intrinsic signaling capacity, rather than reducing the expression 
of the receptor. Indeed, the Western Blot analysis of the dimeric 
mutant receptor indicated no obvious differences from the WT 
receptor, though we cannot rule out that subtle differences in 
expression may have occurred that were not readily detectable 
by western blot (Figure  5). Unfortunately, we were not suc-
cessful in specifically detecting the mature monomeric form 
of the receptor. However, we observed an apparent reduction 
in immature mutant receptor expression which may indicate 
a difference in the maturation of the mutant receptor protein 
and would be interesting to investigate in future studies. This 
study clearly showed that the naturally occurring mutation 
caused disturbances in ligand signaling, the results indicate 
that (Ca2+)i mobilization by the PI-PLC pathway only is par-
tially dependent on CASR-mediated activation, in accordance 
with Goolam et  al. (27). The “gain-of-function” mutation in 
the CASR gene caused a significant increased potency at the 
first point of the PI-PLC signaling pathway, though in the 
later points downstream of the signaling pathway the D126V 
exhibited a significant reduced efficacy, however, the potency 
normalized. In the future, it will be of great interest to evalu-
ate other pathways including Gi/o and G12/13 and the activity of 
intrinsic factors or different molecules, such as microRNA, 
that may contribute to stabilize the intercellular signaling in 
distinct types of cells (24, 25, 27, 34, 35). However, in future 
studies of CASR mutations cells endogenously expressing the 
receptor should be used as direction to assist in verifying clini-
cal relevance of the mutation. Detailed knowledge of D126V 
will allow pharmacologists to design drugs that specifically 
target the molecular determinant that causes the impairments 
observed in ADH (26, 36). Overall, the present study confirms 
that the original model for GPCRs existing in either an “on” 
or “off ” conformation is too simple, also in agreement with 
previous studies (25, 35, 37).
In conclusion, in this study, a family with a clinical diagnosis 
of ADH in two generations was evaluated to identify a mutation 
in the CASR gene and reveal an association between genotype and 
phenotype in the affected family members. The clinical condition 
was caused by a novel, activating, missense mutation (D126V) in 
the CASR gene and the in vitro functional characteristics of the 
mutation co-segregated with their individual phenotype.
eThics sTaTeMenT
Informed consent was given from all participants. The study was 
approved by the Unit of Health Care, Regional Scientific Ethical 
Committee, The Capital Region of Denmark (J.no.17011317).
in a family diagnosed with ADH was identified by analyzing 
the CASR sequence in exon 3, codon 126. The nucleotide sub-
stitution of an A to T resulted in a change from the amino acid 
aspartic acid (D) to valine (V). The genetic and clinical linkage 
of the proband and her children in the investigated family 
showed an autosomal-dominant inheritance pattern, as only 
two of her three children carry the allele with the D126V muta-
tion. According to the summary of the baseline biochemical 
data shown in Table 1, I-2 and II-3 have hypocalcemic status, 
whereas the I-2 and II-2 have low PTH levels. Regarding the 
variable degree of ADH clinical phenotypes as seen in the 
affected family members, it is evident that I-2 and II-3 had 
symptoms of severe hypocalcemia, whereas II-2 had a form of 
asymptomatic mild hypocalcemia, which could indicate that 
the low S-calcium(total) level together with the very low ionized 
calcium level might cause the severe clinical symptoms, as I-2 
and II-3 had 1.9 and 2.1  mmol/L S-calcium(total), respectively 
compared to 2.2 mmol/L S-calcium(total), which is the borderline 
of the reference interval.
The novel D126V mutation described in this study is cen-
trally located in the “Venus FlyTrap” domain and the hot-spot 
area known for gain-of-function mutations in the CASR gene. 
Seventeen different gain-of function mutations have been 
identified in eight codons (http://www.casrdb.mcgill.ca) in 
this functionally important region between amino acid 116 
(alanine) and 131 (cysteine), indicating that this particular part 
of the receptor protein is sensitive to mutation-induced activa-
tion, consistent with the critical importance of this region in 
maintaining the inactive conformation of CASR, which was 
in accordance with the results of Jensen et  al, among others 
(29). Furthermore, the D126V mutation identified in this study 
might alter the binding affinity and/or the dimerization of the 
receptor, as it is placed in this vital region that is highly impor-
tant for the formation of the extracellular loop 2. This loop is 
involved in agonist-induced structural alterations and inter-
molecular disulfide linkages (31), and thus the formation of the 
CASR dimer (32), as described for the N124K mutation (33). 
In this study, we focused on the mechanism by which (Ca2+)o 
activate two key points in the CASR-mediated PI-PLC signal-
ing pathway by characterizing the functional consequences of 
this clinically relevant mutation. In contrast to other studies, 
we investigated the extent to which the heterozygosity had a 
pivotal impact on the functional effects of the CASR, which is 
very important because patients are heterozygous carriers of 
the mutant allele. Hence, we have identified mutation-induced 
impairments, including changes in agonist-stimulated signal-
ing transduction via two distinct points of the PI-PLC pathway, 
IP accumulation and (Ca2+)i mobilization, apparently without 
impaired receptor expression. Regarding the functional analy-
sis of the dose-dependent response to extracellular calcium 
stimulation in the IP accumulation study, the homozygous 
D126V receptor was more sensitive to [Ca2+]o compared to 
the WT receptor as it exhibited a significantly higher potency 
than the WT receptor. The D126V/WT receptor exhibited a 
better function due to the presence of one WT allele (Table 2; 
Figure  3). Surprisingly, the effects of the mutant D126V 
receptor on (Ca2+)i mobilization were strikingly different than 
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